Form 4: IGC Pharma Director James Moran Acquires 588,235 Shares Through Moran Global Strategies

Director James Moran indirectly acquired 588,235 shares of IGC Pharma through Moran Global Strategies, Inc. as part of a share purchase agreement.

Summary

• James Moran, a director of IGC Pharma, indirectly acquired 588,235 shares of IGC common stock on September 25, 2024.
• The shares were purchased at a price of $0.34 per share.
• The purchase was made through Moran Global Strategies, Inc. (MGS), a Virginia corporation owned by James Moran.
• The transaction was conducted under the terms of the 2024 Share Purchase Agreement filed with the SEC on Form 8-K on September 25, 2024.
• Following the transaction, Moran's indirect beneficial ownership totals 942,402 shares.
• Moran disclaims beneficial ownership of the securities except to the extent of any indirect pecuniary interest.

Sentiment

Score: 6

Explanation: The sentiment is neutral. A director buying shares is generally positive, but the disclaimer of beneficial ownership introduces some ambiguity.

Positives

• A director's purchase of shares can be seen as a positive signal, indicating confidence in the company's future prospects.

Risks

• The director disclaims beneficial ownership, except for indirect pecuniary interest, which could suggest a complex ownership structure.

Management Comments

• The Reporting Person hereby disclaims beneficial ownership of all securities, except to the extent of any indirect pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Industry Context

Directors' dealings are closely watched by investors as they can provide insights into the company's prospects. This transaction is a routine disclosure of a director's share purchase.

Related Party Transactions

• The purchase was made through Moran Global Strategies, Inc., a company owned by James Moran, making it a related party transaction.

Stakeholder Impact

• The transaction could have a slightly positive impact on shareholders if interpreted as a sign of confidence from a director.

Key Dates